decitabine + fludarabine + busulfan

A combination chemotherapy and conditioning regimen comprising decitabine, fludarabine, and busulfan. Developed by Hackensack Meridian Health, this regimen is utilized as a reduced-intensity conditioning (RIC) protocol for patients with myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), who are candidates for allogeneic hematopoietic stem cell transplantation. Decitabine serves as a hypomethylating agent that may enhance the sensitivity of malignant cells to subsequent chemotherapy by modulating the epigenetic state of the leukemia cells. Fludarabine, a purine analog, provides potent immunosuppression to prevent graft rejection, while busulfan, an alkylating agent, provides myeloablation to clear the bone marrow for donor cells.

Other names

Decitabine with Fludarabine and Busulfan ConditioningDecitabine + Fludarabine + Busulfan RIC